The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
Open accessAbstract
PURPOSE: Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating peripheral blood mononuclear cells, including antigen presenting cells (APCs), with a fusion protein containing prostatic acid phosphatase. Analysis of data from three phase 3 trials was performed to immunologically characterize this therapy during the course of the three doses, and to relate the immunological responses to overall survival (OS). METHODS: Sipuleucel-T product characteristics [APC numbers, APC activation (CD54 upregulation), and total nucleated cell (TNC) numbers] were assessed in three randomized, controlled phase 3 studies (N = 737). Antigen-specific cellular and humoral responses were assessed in a subset of subjects. The relationships between these parameters and OS were assessed. RESULTS: APC activation occurred in the first dose preparation [6.2-fold, (4.65, 7.70); median (25th, 75th percentile)] and increased in the second [10.6-fold (7.83, 13.65)] and third [10.5-fold (7.89, 13.65)] dose preparations. Cytokines and chemokines associated with activated APCs were produced during the manufacture of each dose; T-cell activation-associated cytokines were detected in the second and third dose preparations. Antigen-specific T cells were detectable after administration of the first sipuleucel-T dose. Cumulative APC activation, APC number, and TNC number correlated with OS (P < 0.05). Antigen-specific immune responses were observed in 78.8 % of monitored subjects and their presence correlated with OS (P = 0.003). CONCLUSION: Sipuleucel-T broadly engages the immune system by activating APCs ex vivo and inducing long-lived immune responses in vivo. These data indicate antigen-specific immune activation as a mechanism by which sipuleucel-T prolongs OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Self-citationAlberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2007) · W.W. Norton eBooks · doi:10.1201/9780203833445 · Cited by 4,589
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Higano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J., Yuh, L., Provost, N., & Frohlich, M. W. (2009) · Cancer · doi:10.1002/cncr.24429 · Cited by 810
Self-citationPrognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 674
Self-citationRuth, S.-D. (1995) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199507000-00004 · Cited by 637
Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells
Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., & Valone, F. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3894 · Cited by 625
Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C. O., de Wit, R., Tannock, I. F., & Eisenberger, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1036 · Cited by 359
Prostate cancer as a model for tumour immunotherapy
Drake, C. G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2817 · Cited by 347
A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses
Chang, S. H., & Dong, C. (2007) · Cell Research · doi:10.1038/cr.2007.35 · Cited by 280
Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8 T Cell Subsets
Willinger, T., Freeman, T., Hasegawa, H., McMichael, A. J., & Callan, M. F. C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5895 · Cited by 261
Burch, P. A., Breen, J. K., Buckner, J. C., Gastineau, D. A., Kaur, J. A., Laus, R., Padley, D. J., Peshwa, M. V., Pitot, H. C., Richardson, R. L., et al. (2000) · PubMed · Cited by 260
Number and distribution of lymphocytes in man. A critical analysis
Trepel, F. (1974) · Klinische Wochenschrift · doi:10.1007/bf01468720 · Cited by 231
Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease
Lohr, J., Knoechel, B., Wang, J. J., Villarino, A. V., & Abbas, A. K. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061341 · Cited by 224
Functions of Granulocyte-Macrophage Colony-Stimulating Factor
Fleetwood, A. J., Cook, A. D., & Hamilton, J. A. (2005) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v25.i5.50 · Cited by 203
Slingluff, C. L., Petroni, G. R., Olson, W. C., Smolkin, M. E., Ross, M. I., Haas, N. B., Grosh, W. W., Boisvert, M. E., Kirkwood, J. M., & Chianese-Bullock, K. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1544 · Cited by 171
Becker, J. T., Olson, B. M., Johnson, L. E., Davies, J. G., Dunphy, E. J., & McNeel, D. G. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dda23e · Cited by 120
Interleukin 1: a common endogenous mediator of inflammation and the local Shwartzman reaction.
Beck, G., Habicht, G. S., Benach, J. L., & Miller, F.-B. V. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.8.3025 · Cited by 118
CD54 is a surrogate marker of antigen presenting cell activation
Sheikh, N. A., & Jones, L. A. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0474-9 · Cited by 116
Self-citationVaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
Neelapu, S. S., Kwak, L. W., Kobrin, C. B., Reynolds, C. W., Janik, J. E., Dunleavy, K. M., White, T., Harvey, L. K., Pennington, R., Stetler‐Stevenson, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1290 · Cited by 111
Sprent, J., Cho, J., Boyman, O., & Surh, C. D. (2008) · Immunology and Cell Biology · doi:10.1038/icb.2008.12 · Cited by 99
McNeel, D. G., NGUYEN, L. D., Ellis, W. J., Higano, C. S., Lange, P. H., & Disis, M. L. (2001) · The Prostate · doi:10.1002/pros.1066 · Cited by 60
Mascio, M. D., Paik, C. H., Carrasquillo, J. A., Maeng, J., Jang, B., Shin, I. S., Srinivasula, S., Byrum, R., Neria, A., Kopp, W., et al. (2009) · Blood · doi:10.1182/blood-2008-12-192203 · Cited by 58
Ai, W. Z., Tibshirani, R. J., Taidi, B., Czerwinski, D. K., & Levy, R. (2009) · Blood · doi:10.1182/blood-2009-01-201988 · Cited by 53
Kirkham, B. W. (1991) · Annals of the Rheumatic Diseases · doi:10.1136/ard.50.6.395 · Cited by 53
Hadaschik, B. A., Su, Y., Huter, E. N., Ge, Y., Hohenfellner, M., & Beckhove, P. (2012) · The Journal of Urology · doi:10.1016/j.juro.2011.11.083 · Cited by 28
Cited by
Dendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2017) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 927
Clinical use of dendritic cells for cancer therapy
Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 700
Cell or Cell Membrane-Based Drug Delivery Systems
Tan, S., Wu, T., Zhang, D., & Zhang, Z. (2015) · Theranostics · doi:10.7150/thno.11852 · Cited by 466
Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M., & Figdor, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1399 · Cited by 377
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A. G., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87624 · Cited by 336
Metadata
- Authors
- Sheikh, N. A., Petrylak, D., Kantoff, P. W., dela Rosa, C., Stewart, F. P., Kuan, L.-Y., Whitmore, J. B., Trager, J. B., Poehlein, C. H., Frohlich, M. W., & Urdal, D. L.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2012-08-03
- Volume
- 62
- Issue
- 1
- Pages
- 137-147
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2170805832
- Cited by
- 263
- References
- 27
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.